

Body Mass Index, Components of Metabolic Syndrome and Hyperuricemia among Women in Postmenopausal Period

Vladyslav Povorozyuk, Galina Dubetska, Roksolana Povorozyuk

Abstract—In recent years, the problem of hyperuricemia is getting a particular importance due to its increased incidence in the world population. The aim of this study was to determine uric acid level in blood serum, incidence of hyperuricemia among women in postmenopausal period and their association with body mass index and some components of metabolic syndrome (triglyceride, cholesterol, systolic and diastolic pressure). We examined 412 women in postmenopausal period. They were divided in to the following groups: I group (BMI = 18,5-24,9), II group (BMI = 25,0-29,9), III group (BMI = 30,0-34,9), IV group (BMI > 35). We determined uric acid level among women during postmenopausal period depending on their body mass index. The higher level of uric acid was found in patients with the maximal body mass index (BMI > 35). In the I group it was $277,52 \pm 8,40$; in the II group – $286,81 \pm 7,79$; in the III group – $291,81 \pm 7,56$; in the IV group – $327,17 \pm 12,17$. Incidence of hyperuricemia among women in the I group was 10,2%, in the II group – 15,9%; in the III group – 21,2%, in the IV group – 34,2%. We found an interdependence between an uric acid level and BMI in the examined women ($r = 0,21$, $p < 0,05$). We determined that the highest level of triglyceride ($F = 18,62$, $p < 0,05$), cholesterol ($F = 3,64$, $p < 0,05$), atherogenic coefficient ($F = 22,64$, $p < 0,05$), systolic ($F = 10,5$, $p < 0,05$) and diastolic pressure ($F = 4,30$, $p < 0,05$) was among women with hyperuricemia. It was an interdependence between an uric acid level and triglyceride ($r = 0,26$, $p < 0,05$), atherogenic coefficient ($r = 0,24$, $p < 0,05$) among women in postmenopausal period.

Keywords—Hyperuricemia, uric acid, body mass index, metabolic syndrome, triglyceride, cholesterol, atherogenic coefficient, systolic and diastolic pressure, women.

I. INTRODUCTION

THE study of the problem of hyperuricemia is relevant in connection with the significant spread of this pathology in the world population. Hyperuricemia is considered to be an increased content of uric acid in the blood serum totaling over 360 $\mu\text{mol/l}$ (≤ 6 mg/dL) [16]. This rate is a treatment reference point for the patients suffering from gout to be prescribed medications that reduce the content of uric acid and urates in their bodies [10]. The prevalence of hyperuricemia in various regions varies significantly: 2% – 20% [8], [9], [11], [12].

V. Povorozyuk is with the D.F. Chebotarev Institute of Gerontology of NAMS of Ukraine, Kyiv, 04074 Ukraine (phone: 38-097-3734189; fax: 38-044-4304174; e-mail: okfpodac@ukr.net).

G. Dubetska is with D.F. Chebotarev Institute of gerontology NAMS Ukraine, Kyiv, Ukraine (e-mail: dgs_27_05t@ukr.net).

R. Povorozyuk is with Institute of Philology, Kyiv National Taras Shevchenko University, Kyiv, Ukraine (e-mail: rocksol24@yandex.ru).

Uric acid is the end product of purine outbreak excreted by kidneys. Within 24 hours, healthy people excrete up to 400-600 mg of uric acid with urine.

Studying the peculiarities of the development of hyperuricemia in post-menopausal women is very important. Medical scientific sources state that high level of estrogens in women of reproductive age contributes to maintenance of normal renal clearance of urates [6], [7].

Scientific studies show that hyperuricemia develops not only with gout but also with other morbid conditions. Hyperuricemia correlates with the development of obesity, metabolic syndrome, arterial hypertension, intake of diuretics and a low-dosed acetylsalicylic acid, elderly age and with bone mineral density [2], [17], [19], [21], [23], [24]. Elevated serum uric acid levels have been associated with an increased risk of cardiovascular diseases and metabolic syndrome and are often reported to be higher in females than in males [1], [3], [13], [15], [18], [20], [22].

There are data of the sex- and age-specific association between serum uric acid level and body mass index: in women the incidence of hyperuricemia increased with age; in men – decreased. The results of scientific studies showed that deficient weight in women aged 20 to 29 years and in men aged 20 to 69 years was associated with a lower prevalence of hyperuricemia. Obesity is a risk factor for metabolic syndrome, arterial hypertension, diabetes mellitus, hyperuricemia [4], [5], [14].

The aim of this study is to determine uric acid level in blood serum and incidence of hyperuricemia among women in postmenopausal period and their association with body mass index and some components of metabolic syndrome (triglyceride, cholesterol, systolic and diastolic pressure).

II. MATERIALS AND METHODS

We studied the patients of the Physiology and Pathology of Bone and Joint Diseases department and the Ukrainian Scientific-Medical Center of Osteoporosis. All of them were women in postmenopausal period ($n = 412$). They were divided in following groups: I group (BMI = 18,5-24,9), II group (BMI = 25,0-29,9), III group (BMI = 30,0-34,9), IV group (BMI > 35).

Average age of the examined patients was $64,3 \pm 0,8$ years. Patients were hospitalized to the clinic of Physiology and Pathology of Bone and Joint Diseases by the Institute of Gerontology, AMS of Ukraine.

We performed a retrospective analysis of patients' case

histories (medical records). Uric acid level in blood plasma was determined by uricase-peroxidase method. "Statistika 6.0" (StatSoft, Inc.©) was used for data processing purposes. Significance was set at $p < 0.05$.

III. RESULTS

Uric acid level among women during postmenopausal period depended on body mass index.

The higher level of uric acid was found in patients with the maximal body mass index ($BMI > 35$). In the I group it was $277,52 \pm 8,40$; in the II group – $286,81 \pm 7,79$; in the III group – $291,81 \pm 7,56$; in the IV group – $327,17 \pm 12,17$ ($F = 4,19$; $P < 0,05$) (Fig. 1).

Incidence of hyperuricemia among women in the I group was 10,2 %, in the II group – 15,9 %; in the III group – 21,2%, in the IV group – 34,2%.

We found correlations between uric acid level and BMI in the examined group ($r = 0,21$, $p < 0,05$) (Fig. 2).




Fig. 3 Interdependence between uric acid level and triglyceride in the examined women




Fig. 1 Uric acid level among women during a postmenopausal period depending on their body mass index




Fig. 4 Interdependence between uric acid level and cholesterol in the examined women




Fig. 2 Correlations between uric acid level and body mass in the examined women




Fig. 5 Interdependence between uric acid level and atherogenic coefficient in the examined women

We determined that the highest level of triglyceride ($F = 18,62, p < 0,05$), cholesterol ($F = 3,64, p < 0,05$), atherogenic coefficient ($F = 22,64, p < 0,05$), systolic ($F = 10,5, p < 0,05$) and diastolic pressure ($F = 4,30, p < 0,05$) was among women with hyperuricemia (Figs. 3-7).




Fig. 6 Interdependence between uric acid level and systolic pressure in the examined women




Fig. 7 Interdependence between uric acid level and diastolic pressure in the examined women

It was an interdependence between an uric acid level and triglyceride ($r = 0,26, p < 0,05$) and atherogenic coefficient ($r = 0,24, p < 0,05$) among women in postmenopausal period (Figs. 8, 9).

IV. CONCLUSION

It was determined that uric acid level among women during a postmenopausal period depended on body mass index. The higher level of uric acid was found in patients with the maximal body mass index ($BMI > 35$). We also found correlations between uric acid level and BMI in the examined

group.




Fig. 8 Correlations between uric acid level and triglyceride in the examined women




Fig. 9 Correlations between uric acid level and atherogenic coefficient in the examined women

The highest level of triglyceride, cholesterol, atherogenic coefficient, systolic and diastolic pressure was among women with hyperuricemia.

It was an interdependence between an uric acid level and triglyceride and atherogenic coefficient among women in postmenopausal period.

REFERENCES

- [1] Chiou W, Wang M, Huang D, et al. The Relationship between Serum Uric Acid Level and Metabolic Syndrome: Differences by Sex and Age in Taiwanese. *J Epidemiol.* 2010;20(3):219-224. DOI: 10.2188/jea.JE20090078.
- [2] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med.* 2008;359(17):1811-1821. DOI: 10.1056/NEJMr0800885.
- [3] Koga M, Saito H, Mukai M, Kasayama SY. Factors contributing to increased serum urate in postmenopausal Japanese females. *Climacteric.* 2009;12(2):146-152. DOI: 10.1080/13697130802607719.
- [4] Kuwabara M, Kuwabara R, Niwa K et al. Different Risk for

- Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. *Nutrients*. 2018;10(8):1011. DOI: 10.3390/nu10081011.
- [5] Liu DM, Jiang LD, Gan L, Su Y, Li F. Association between serum uric acid level and body mass index in sex- and age-specific groups in southwestern China. *Endocr Pract*. 2019;25(5):438-445. DOI: 10.4158/EP-2018-0426.
- [6] Povoroznyuk VV, Dubetska GS. Hyperuricemia and age. *Gerontologija*. 2012; 13(3):149-153.
- [7] Terkeltaub R. Gout and other crystal arthropathies. 2012:357. <https://www.elsevier.com/gout-and-other-crystal-arthropathies/terkeltaub/978-1-4377-2864-4>.
- [8] Trifiro G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricemia in Italy during the years 2005-2009: a nationwide population-based study. *Ann Rheum Dis*. 2013;72(5):694-700. DOI: 10.1136/annrheumdis-2011-201254.
- [9] Wallace KL. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. *J Rheumatol*. 2008;31(8):1582-1587.
- [10] Watanabe S. Uric acid, huminoid evolution and the pathogenesis of salt-sensitivity. *Hypertension*. 2002;40:355-360.
- [11] Wu LJ, Song XY. Epidemiological study on hyperuricemia and gout in Uygur population in Turpan area of Xinjiang. *Beijing Da Xue Xue Bao*. 2012;44(2):250-253.
- [12] Yamanaka H. Gout and hyperuricemia in young people. *Curr Opin Rheumatol*. 2011;23(2):156-160.
- [13] Yang T, Chu CH, Bai CH, et al. Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. *Atherosclerosis*. 2012;220(2):525-531. DOI: 10.1016/j.atherosclerosis.2011.11.014.
- [14] Yue JR. Association of serum uric acid with body mass index among long-lived Chinese. *Exp Gerontol*. 2012;47(8):595-600.
- [15] Zhang Q, Lou S, Meng Z, Ren X. Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. *Clin Rheumatol*. 2011;30(6):777-787. DOI: 10.1007/s10067-010-1660-7.
- [16] Zhang W. EULAR evidence based recommendation for gout. *Ann Rheum Dis*. 2006;10:1301-1311.
- [17] Zhang Y. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. *Mol Cell Endocrinol*. 2013;375(1-2):89-96.
- [18] Zhang L. Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. *Am J Epidemiol*. 2013;177(9):923-32.
- [19] Zhang HW. A cross-sectional study on serum uric acid level and the distribution of metabolic syndrome among Uigur, Han and Kazak prediabetic groups in Xinjiang. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2013;34(10):958-960.
- [20] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum*. 2011;63(10):3136-3141. DOI: 10.1002/art.30520.
- [21] Zoppini G. The role of serum uric acid in cardiovascular disease in Type 2 diabetic and non-diabetic subjects: A narrative review. *J Endocrinol Invest*. 2011;34(11):881-886.
- [22] Zoccali C, Mallamaci F. Uric acid, hypertension, and cardiovascular and renal complications. *Curr Hypertens Rep*. 2013;15(6):531-537. DOI:10.1007/s11906-013-0391-y.
- [23] Zoccali C. Uric acid, hypertension, and cardiovascular and renal complications. *Curr Hypertens Rep*. 2013;15(6):531-537.
- [24] Ziaee A. Association between Uric Acid and Metabolic Syndrome in Qazvin Metabolic Diseases Study (QMDS), Iran. *J Health Sci*. 2012;5(1):155-165.